Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Isis Pharmaceuticals has commenced two randomized, controlled Phase 2 studies of ISIS-EIF4ERx in patients with non-small cell lung cancer and prostate cancer.
Subscribe to our email newsletter
ISIS-EIF4ERx targets the gene that is responsible for the production of a protein, eIF-4E, which is over-expressed in a variety of cancers, including prostate, lung, ovarian, liver, breast, head and neck, bladder, colon, thyroid and lymphoma.
According to Isis Pharma, the first Phase 2 study is investigating ISIS-EIF4ERx’ssafety and efficacy in combination with carboplatin and paclitaxel in patients with non-small cell lung cancer.
However, the second Phase 2 study is evaluating the safety and efficacy of ISIS-EIF4ERx in combination with docetaxel and prednisone in patients with castrate-resistant prostate cancer.
The endpoints for both studies include progression-free survival, response rates, overall survival, time to progression and the reduction of a variety of biomarkers.
Isis Pharma Drug Discovery & Corporate Development vice president Brett Monia said that eIF-4E may represent a novel and applicable target for cancers because it promotes cancer cell growth in many types of cancer.
"In the Phase 1 study, ISIS-EIF4ERx reduced eIF-4E in tumors and was well tolerated at doses up to 1200 mg per week in patients with a variety of cancers," Monia said.
"Initially, our Phase 2 program will evaluate ISIS-EIF4ERx in combination with first-line treatments in prostate cancer and non-small cell lung cancer."